February 15, 2018 / 11:43 AM / in 9 months

BRIEF-Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1

Feb 15 (Reuters) - Merck & Co Inc:

* SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR NEUROFIBROMATOSIS TYPE 1

* MERCK & CO INC - ‍FDA GRANTED ORPHAN DRUG DESIGNATION FOR SELUMETINIB, A MEK 1/2 INHIBITOR, FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1​

* MERCK & CO INC - PHASE II TRIAL RESULTS FOR SELUMETINIB ARE EXPECTED LATER IN 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below